Benchmark International 
Benchmark International 
Political and economic uncertainty caused pharma M&A to slacken off in 2016, seeing deal values in the sector falling to $273.7bn from $392.4bn the previous year. While 2016 was far from catastrophic for pharma M&A it failed to reach the all-time highs achieved from the mega-deals in 2015, and the collapse of the $160bn mega-deal between Pfizer and Allergan was just one of the year’s setbacks for the sector.
READ MORE >>Archives
Pharma companies set for another big year for M&A
Posted on February 1, 2017 By
Benchmark International in
Allergan +
Benchmark International +
Chinese M&A +
Deal Making +
Donald Trump +
Genentech +
Merck +
mergers +
Roche +
Schering-Plough +
Shanghai Henlius Biotech +
US +
Acquisitions +
Blog +
China +
Jiangsu Hengrui Medicine +
Mergers and Acquisitions +
Pfizer +
Pharma +
Pharma M&A +
USA +
Wyeth
Post-Holiday Boost Predicted For M&A
Posted on September 15, 2016 By
Benchmark International in
Benchmark International +
Medivation +
mergers +
Oranges +
US Election +
Acquisition +
Acquisitions +
Apples +
Brexit +
Business +
M&A +
Mergers and Acquisitions +
Pfizer +
Presidential Election +
Thomson Reuters
Following a summer of uncertainty post Brexit, investors all over the world are returning from summers spent on the beach, ready to do some serious M&A business to close out the year.
READ MORE >>Share this:
Why The Appetite For M&A In Healthcare Stays Strong
Posted on July 6, 2016 By
Benchmark International in
Allergan +
Anacor +
Benchmark International +
Medivation +
mergers +
AbbVie +
Acquisition +
Acquisitions +
AstraZeneca +
Biotechs +
Blog +
Business +
healthcare +
M&A +
Mergers and Acquisitions +
Pfizer +
Sanofi +
Stemcentrx
M&A Activity Hits an All Time High
Posted on June 30, 2016 By
Benchmark International in
Allergan +
Benchmark International +
Bloomberg +
DuPont +
Ernst & Young +
General Electric +
Horizontal Mergers +
mergers +
AB Inbev +
Acquisition +
Acquisitions +
Blog +
Business +
Dow +
M&A +
Mergers and Acquisitions +
Pfizer +
SABMiller +
USA
The corporate industry world has borne witness to some of the mega deals being signed throughout the year. Pharmaceutical giant Pfizer announced as $160 billion merger with Allergan. A deal that was, according to Bloomberg, “the largest ever deal in the history of healthcare industry and second biggest deal overall on record”.
READ MORE >>